<DOC>
	<DOC>NCT02832167</DOC>
	<brief_summary>The purpose of this study is to determine whether Nivolumab is an effective treatment for advanced or metastatic cancer. The study will evaluate the clinical benefit rate of Nivolumab in subjects at 16 weeks from enrollment. Various advanced or metastatic tumor types are eligible for enrollment. Subjects must have received prior standard of care treatment for their cancer before enrollment.</brief_summary>
	<brief_title>An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Diagnosed with advanced or metastatic malignancy Received standard of care treatment for primary malignancy and standard of care treatment for relapsed cancer Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Prior treatment with an antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody, or any other antibody or drug specifically targeting Tcell costimulation or checkpoint pathways. Subjects previously treated with investigational anticancer therapies less than 6 weeks prior to the first dose of Nivolumab Subjects with an active, known, or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>